EBD Group is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
Key Sessions

Dieter Weinand

Keynote

Bayer AG

Kate Bingham

Opening Plenary - Breaking down walls: Keeping collaboration at the center of biotech

SV Health Investors

Nov 06
Show Filter
07:45 - 18:00 615 mins
Main agenda
Registration open
more

Entrance Level, Entrance Lobby

07:45 - 10:30 165 mins
Main agenda
Continental Breakfast
more

Level 2, Hall B

07:45 - 18:00 615 mins
Main agenda
Exhibition Open
more

Level 2, Hall B

09:00 - 10:30 90 mins
Main agenda
Routes of commercialization
  • Moderator Anna Casse - Managing Partner, Alacrita
  • Panelist Johannes Clemens - Director, Business Development Europe, Vetter Pharma International
  • Panelist Laurent Foetisch - Managing Director, Supply Chain Operations SA
  • Panelist Anant Murthy - VP, Market Access & Policy, Europe & Canada, Alnylam Pharmaceuticals
  • Panelist Matthew Zustiak - Head of Upstream Process Development, Patheon, part of Thermo Fisher Scientific
more

Level 3, Room M8

This panel will discuss the market access strategies, transitions to and from the clinic, supply chain development, and partnering approaches that allow a company to juggle the dynamic, changing requirements of the commercialization process.  The panelists will address issues from early stage to launch, and will use real world examples to illustrate how constant forward planning, early regulatory engagement and a flexible partnering strategy is essential to commercial success.

09:00 - 10:30 90 mins
Main agenda
The evolving role of Real World Evidence in regulatory approval and reimbursement decisions
  • Moderator Leora Schiff - Principal, Altius Strategy Consulting
  • Panelist Stella Blackburn - VP, Global Head, Early Access and Risk Management, RWES, QuintilesIMS
  • Panelist Athula Herath - Global Head, Real World Evidence Disease Epidemiology, Novartis
  • Panelist Janice Haigh - VP and Global Head, Pricing and Market Access, PAREXEL Access Consulting
more

Level 3, Room M4

Panelists discuss how real world data is impacting clinical development today.  This session will identify the groups in the development process that demand real world evidence, what they are looking for and the considerations that companies need to plan for in order to ensure effective implementation of data.

09:00 - 10:30 90 mins
Main agenda
Successful corporate communications in a changing media and investment world
  • Moderator Ludger Weß - Managing Partner, akampion
  • Panelist Stephen Hansen - Associate Editor, BioCentury
  • Panelist Sascha Karberg - Science Writer, transkript/Tagesspiegel
  • Panelist Eva V. Schaper - Science Writer, Freelance
  • Panelist Cormac Sheridan - Science Journalist, BioWorld Today
  • Panelist Mike Ward - Global Director of Content, Informa Pharma Insights
more

Level 3, Room M6

Biotech companies increasingly have difficulties getting their story across to media and the investment community. For one, more and more media cannot afford trained science journalists any more. Their successors usually don’t have a background in science, are not familiar with the industry and lack a carefully built network of science and industry specialists adamant for the gathering and evaluation of news.

On the other hand, many biotech professionals still underestimate the role of having a clear story and vision they can pitch to investors to convince them of a solid business case. This has become increasingly important as many biotech companies have started to look for investors outside the traditional biotech investment community.

Therefore, biotech companies need to communicate their progress to a larger audience. This is not only important for public companies. Private companies, too, must develop broad communication skills in order to succeed. In this panel, we will discuss the needs of both healthcare-savvy media / investors and generalists and how companies can address these needs.

10:00 - 18:30 510 mins
Main agenda
One-to-one Meetings
more

Level 1, Hall A

10:45 - 11:15 30 mins
Main agenda
Welcome and Opening Remarks
  • Speaker Anna Chrisman - Group Managing Director, EBD Group and KNect365 Life Sciences
  • Kai Bindseil - Head of Division, Life Sciences | Healthcare Industries, Berlin Partner
  • Christian Rickerts - State Secretary, Economy, Energy and Enterprises, State of Berlin
  • Speaker David Thomas - Senior Director, Industry Research and Analysis, Biotechnology Innovation Organization (BIO)
more

Level 3, Room M1

11:15 - 11:30 15 mins
Main agenda
Keynote
  • Speaker Dieter Weinand - Member of the Board of Management and President Pharmaceuticals, Bayer AG
more

Level 3, Room M1

11:30 - 12:30 60 mins
Main agenda
Opening Plenary - Breaking down walls: Keeping collaboration at the center of biotech
  • Moderator Kate Bingham - Managing Partner, SV Health Investors
  • Panelist Zaki Hosny - Senior Advisor, Albright Stonebridge Group
  • Panelist Hans Lindner - Head, Global External Innovation and Alliances, Bayer
  • Panelist Richard Mason - Head of London Innovation Centre, Johnson & Johnson Innovation, EMEA
  • Panelist Ulrich Wendt - Head, Diabetes External Innovation, Sanofi
more

Level 3, Room M1

Biotech has thrived because of the collaborative nature of its business model. The plenary session will address the new walls being erected within the industry, in policy, business, and science, which will require the same cooperation to break down.

12:00 - 14:00 120 mins
Main agenda
Luncheon
more

Level 2, Hall B; Hall 2 (access via Hall B)

13:30 - 14:30 60 mins
Main agenda
Developing solutions for pediatric diseases
  • Moderator Hubert Birner - Managing Partner, TVM Life Science Management and TVM Capital
  • Panelist Elizabeth Aylward - Director, Office of Science-Industry Partnerships, Seattle Children’s Research Institute
  • Panelist Arndt Rolfs - CEO, Centogene
  • Panelist Chris Schelling - CEO, Acer Therapeutics
  • Panelist Kim Stratton - Head, International Commercial, Shire
more

Level 3, Room M4

The pediatric disease area is at the forefront of partnering models. The constellation of research hospitals, agile biotech companies, pharma expertise, and active funding bodies is producing a vibrant network of collaboration to develop treatments for a broad number of pediatric diseases. This panel will examine some of the successful models which are currently working for solutions to a number of rare diseases.

14:45 - 15:45 60 mins
Main agenda
Targeting the microbiome: From scientific evidence to regulatory approval
  • Moderator Douglas MacDougall - President, MacDougall Biomedical Communications
  • Panelist Patrice Cani - Université Catholique de Louvain, FNRS-WELBIO, Brussels, Belgium
  • Panelist Isabelle de Cremoux - CEO, Seventure
  • Panelist Nigel Crockett - Head, Business Development, Microbiotica
  • Panelist David Donabedian - Co-Founder and CEO, Axial Biotherapeutics
more

Level 3, Room M4

In recent years, scientific evidence has turned the spotlight on the microbiome as a separate organ that plays a vital role in many human diseases. As a result, funding for microbiome companies continues to grow rapidly, setting the stage for more companies to explore the therapeutic value of harnessing the microbiome to develop novel treatments. As the microbiome field shifts from scientific proof-of-concept stage towards product development, new challenges are raised in respect to choosing effective development pathways to reach the appropriate market segments. There is a variety of strategies to choose from in the microbiome field, whether companies are focused on developing new medicines and medical nutrition, products for health maintenance, which can be sold as OTC products, nutritional supplements or functional foods; or, occasionally, microbiome-derived products approved as medical devices. Innovative companies in the field need to select the best clinical and regulatory pathway for their product plan based on their scientific knowledge and their projected strategy. This involves early choices such as: which customers to target, which modality to base the product on (live organism(s), biologics, small molecules), which regulatory regimen to choose (prescription drug, food, device—and the many subdivisions of each of those categories), and what are the operational and financial consequences of these choices on the company’s business plan. Join us as we discuss examples of different pathways to pursue, steps where the collaboration with regulatory agencies is required, and how to mix the different ingredients for a successful business strategy.

16:00 - 17:00 60 mins
Main agenda
Cell and gene therapies: The keys to the future of healthcare
  • Moderator Morrie Ruffin - Managing Partner, Adjuvant Partners
  • Panelist Sharon Brownlow - Head of Collaborations, Manufacturing Centre,, The Cell and Gene Therapy Catapult
  • Panelist Gabriele Proetzel - Director, Regenerative Medicine, Takeda
  • Panelist Shai Yarkoni - CEO, Cellect Biotechnology Ltd
  • Panelist Andrew Yost - VP, Corporate Development, REGENXBIO Inc.
more

Level 3, Room M4

Exciting breakthroughs in cell and gene therapies, from new approvals to cutting-edge research discoveries, are creating new opportunities and challenges for the industry. What strategies are companies using to develop, manufacture, and commercialize these life-changing treatments and cures? How are partnerships critical to successfully advancing the science to becoming viable commercial products?

17:15 - 18:15 60 mins
Main agenda
Next wave immunotherapy: The future including and beyond checkpoints
  • Moderator Joel Sandler - Associate Principal, Defined Health
  • Panelist Kaan Certel - Head of External Innovation Oncology, Business Development and Licensing, Sanofi
  • Panelist Nouhad Husseini - VP, Head of Business Development, Regeneron
  • Panelist Bernd Mühlenweg - Chief Business Officer, Nanobiotix
  • Panelist Matt Roden - VP, Global Business Development Assessment and Strategic Corporate Development, Bristol-Myers Squibb
more

Level 3, Room M4

With immune checkpoint inhibitors such as Yervoy, Opdivo, and Keytruda having demonstrated an ability to extend survival across heavily pretreated tumor types, all eyes are now looking ahead to how the effect of size and addressable patient populations can be expanded upon. Indeed, a range of modalities have emerged as potential candidates for checkpoint combination regimens, each poised to address “cold” or otherwise IO-resistant patients. Many questions still exist, including which mechanisms will be best suited to unleash the full power of the anticancer immune response, in what patients, and over what time horizons will various developments continue to play out. Join our distinguished panel as we discuss and debate some of the finer points surrounding clinical and commercial issues in oncology and look to achieve a deeper understanding about who and how to achieve relevance in the emerging IO landscape.

13:30 - 14:30 60 mins
Main agenda
Funding Discovery
  • Moderator Steve Dickman - CEO, CBT Advisors
  • Panelist Philipp Bürling - CFO and Co-Founder, NUMAFERM GmbH
  • Panelist Jon Edwards - Principal, Medicxi
  • Panelist Andrew Hopkins - CEO, Exscientia
  • Panelist Raphael Wisniewski - Partner, Edmond de Rothschild Investment Partners
more

Level 3, Room M1

Funding the early stages of company development can be a challenge but it also provides opportunity for innovation, new partners, and first chance to prove the viability of an idea. This panel will use the recent experiences of biotech companies to explore how the funding process contributed to the companies' positive development and growth.

14:45 - 15:45 60 mins
Main agenda
What the deals of 2017 mean for 2018
  • Moderator Sam Ulin - Principal, ClearView Healthcare Partners
  • Panelist Paul Hadden - Managing Director, HealthCare Royalty Partners
  • Panelist Ji Li - Executive VP and Global Head of Business Development, BeiGene
  • Panelist Barbara Sosnowski - VP, External R&D Innovation, Pfizer
  • Panelist Ben Thorner - Senior VP, Business Development and Licensing, MSD
more

Level 3, Room M1

This panel will examine the deal trends of 2017. What are the drivers? Who are the players? What are the structures? Can we expect to see these trends continue into 2018? Join us for a deep dive into the deals of 2017.

16:00 - 17:00 60 mins
Main agenda
Building the future of the European public market
  • Moderator Olivier Litzka - Partner, Edmond de Rothschild Investment Partners
  • Panelist Ulrica Slåne Bjerke - Founder and CIO, Arctic Fund Management
  • Panelist Sebastian Grabert - Director – Germany Representative (Munich), Euronext
  • Panelist Oscar Izeboud - Managing Director, NIBC Bank
  • Panelist Simon Moroney - CEO, MorphoSys
  • Panelist Peter Rahmer - Managing Director, The Trout Group LLC
more

Level 3, Room M1

The European biotech market has much going for it: strong M&A, strong investment, exciting young companies with the potential for lucrative exits. This session will discuss how the strengths of the industry can be consolidated through the further development of a European public market.

17:15 - 18:15 60 mins
Main agenda
Answering the million dollar question: Partner or go it alone?
  • Moderator Neel Patel - Managing Director, INC Research/inVentiv Health Consulting
  • Panelist Margarita Chavez - Managing Director, AbbVie Ventures
  • Panelist Jennifer Laird - Senior Director, Neuroscience, Eli Lilly
  • Panelist Brendan Luu - Head, Business Development, Technologies and Externalizations, Merck KGaA
  • Panelist Nerida Scott - VP, New Ventures and Transactions, Johnson & Johnson Innovation
more

Level 3, Room M1

Dealmaking in life sciences has been robust in 2017 and remains a seller’s market as buyers narrow their therapeutic areas of focus and fiercely compete for entry and leadership in hot therapeutic areas. At the same time, true innovators can expect to benefit from the emergence of new buyers and more financing options from the capital markets as well as unique partnering and outsourcing scenarios, permitting them to hold on to assets through to commercialization in some disease areas. This panel will discuss the many opportunities available to sellers and considerations for making the decision between partnering and going it alone.

13:30 - 14:30 60 mins
Main agenda
Life sciences in China: The future is bright
  • Moderator Ruediger Herrmann - Partner, Corporate Life Sciences, Dechert LLP
  • Panelist Darren Ji - CEO, Elpiscience Pharmaceuticals, Inc; Venture Partner, Lilly Asia Ventures
  • Panelist Joyce Pei - Executive Director, Simcere Pharmaceutical Group
  • Panelist Jonathan Wang - VP, Head Business Development, Zai Lab
more

Level 3, M6

There’s been no better time to partner with companies in China. With record-breaking investments in and outbound, a positive regulatory environment that supports innovation in China, and the fastest growing pharmaceutical market in the world, companies and investors are eager to make the most of these opportunities now. Leaders in this field will discuss the partnering and investment opportunities in China.

14:45 - 15:45 60 mins
Main agenda
Navigating Brexit
  • Moderator Mike Ward - Global Director of Content, Informa Pharma Insights
  • Panelist Laura Collister - Brexit Lead, BIA
  • Panelist John Haurum - CEO, F-star GmbH
  • Panelist Werner Lanthaler - CEO, Evotec
  • Panelist Aimad Torqui - Director Global Regulatory Policy, MSD
more

Level 3, Room M6

This panel will explore what Brexit really means for biopharma companies (both UK and continental European). Panelists will discuss how executives are planning (or should plan) for the changes that the separation will inevitably bring to the biotech industry, highlighting both the opportunities and challenges, as well identifying potential winners and losers.

15:45 - 16:00 15 mins
Main agenda
Keynote: UK life sciences and Brexit
  • Speaker Lord O’Shaughnessy - Parliamentary Under Secretary of State, Department of Health, UK Government
more

Level 3, Room M6

13:45 - 14:00 15 mins
Main agenda
Bristol-Myers Squibb
more

Matt Roden - Vice President, Global Business Development Assessment and Strategic Corporate Development

14:00 - 14:15 15 mins
Main agenda
Bayer
more

Dmitrij Hristodorov - Director Early Licensing

14:15 - 14:30 15 mins
Main agenda
MSD
more

Phil L’Huillier - Head, European Innovation Hub

14:30 - 14:45 15 mins
Main agenda
Eli Lilly & Company
more

Johnston Erwin - Vice President Corporate Business Development

14:45 - 15:00 15 mins
Main agenda
Novo Nordisk
more

Florence Dal Degan - R&D Innovation Sourcing Director

15:00 - 15:15 15 mins
Main agenda
AbbVie
more

Ben Julian - Senior Director, Business Development and Acquisitions

15:15 - 15:30 15 mins
Main agenda
Sanofi
more

Kaan Certel - Head of External Innovation, Oncology

15:30 - 15:45 15 mins
Main agenda
Merck
more

Philippe Lopes-Fernandes - Senior VP, Head of Global Licensing and Business Development

15:45 - 16:00 15 mins
Main agenda
Amgen
more

Olaf Koenig - Director of Business Development

16:00 - 16:15 15 mins
Main agenda
Novartis Pharma
more

Markus Kalousek - Global Head Pharma S&E, BD&L

16:15 - 16:30 15 mins
Main agenda
Roche
more

Hans Trees - Director Strategic Partnering

16:30 - 16:45 15 mins
Main agenda
Genentech
more

Amit Mehta - Senior Manager, Business Development, Ophthalmology

16:45 - 17:00 15 mins
Main agenda
Servier
more

Corinne Venot - Lead Project Director Oncology BD&L

17:00 - 17:15 15 mins
Main agenda
Pfizer
more

Tania Dimitrova - Director, Worldwide Business Development

17:15 - 17:30 15 mins
Main agenda
Boehringer Ingelheim
more

Dr. Emilio Erazo-Fischer - Associate Director of Global Oncology Business Development & Licensing

17:30 - 17:45 15 mins
Main agenda
Johnson & Johnson Innovation
more

Rosemary Liu - New Ventures & Transactions Lead, Cardiovascular & Metabolic Diseases

15:15 - 16:45 90 mins
Main agenda
Post-signing challenges in transatlantic licensing and co-development agreements: Legal and operational perspectives
  • Moderator Henning Mennenöh - Partner, Weitnauer
  • Speaker Mark Cooper - Of Counsel, Faber Daeufer & Itrato PC (former VP and Assistant General Counsel Business Transactions, Research & Development, Pfizer Inc.)
  • Speaker Anthony Hörning - Founder, Strategic Transactions Advisory AG, (former Global Head of Alliance Management, Novartis Pharma)
more

Level 3, Room M7

We shall juxtapose a “contractually-oriented, US perspective” with an “operational, European” one. What are the cultural and legal differences in the approaches to strategic alliances between US and European companies? What challenges derive from this analysis for the leaders of partnering companies? Topics: Identifying and challenging pre-conceived views US and European companies have of each other, differences in approaches to contracts and decision-making, how companies find “common ground” or agreement on difficult issues, exploring alternative solutions to problems and resolving conflict.

16:05 - 16:25 20 mins
Main agenda
Break and Breathe
more

Level 3, Room M8

Enhance your conference experience by using simple breathing techniques, movement and light stretches in order to charge your body and mind for better decision making and more energy throughout the day. 

Open to all. No prerequisites required. Standing and seated positions only.


17:00 - 18:30 90 mins
Main agenda
bioXclusters plus Seminar and Beer Reception: Global Gateways for European life science clusters and their companies
more

Level 3, Room M6

As part of the bioXclusters plus initiative (www.bioXclusters.eu), global clusters and network organizations, named “Gateways,” offer services to European clusters and their companies to enter non-European key markets and to find the right business partners. This seminar provides information about such internationalization services, open to all European regions, networks and science parks and companies. 

After presentations from selected global gateway organizations, a “Berliner Weisse” beer reception offers the opportunity to exchange business cards and to network with European and global contacts.

Confirmed Gateway presentations (further are pending):

* ToHealth!, Toronto, Canada

* Osaka BioHeadquarters / Osaka Prefecture, Japan

* Health Industries SA

No registration is required.

But if possible, please confirm your attendance to Emilie Romeo, project leader bioXclusters plus- Lyonbiopole, at emilie.romeo@lyonbiopole.com.

17:05 - 17:25 20 mins
Main agenda
Break and Breathe
more

Level 3, Room M8

Enhance your conference experience by using simple breathing techniques, movement and light stretches in order to charge your body and mind for better decision making and more energy throughout the day. Open to all. No prerequisites required. Standing and seated positions only.

17:45 - 18:45 60 mins
Main agenda
Speed Matters! Race against your peers...
more
Join us at the Carrera® race track lounge and be the winner.

Sponsored by: JSR Life Sciences

Location: Exhibition – Hall B

18:00 - 18:45 45 mins
Main agenda
Champagne reception at EBD Group booth
19:00 - 22:00 180 mins
Main agenda
Evening Networking Reception with Buffet-style Dinner
more

Venue: 

Palais am Funkturm | Hammarskjöldplatz | 14055 Berlin

The Palais am Funkturm is Berlin’s largest ballroom—a venue for balls, banquets and receptions, with the unique charm of the 50s. With its elegantly curved patterns and original interior it is a highly popular party location. Experience the exclusive atmosphere under a ceiling decorated with gold leaf as well as the impressive sandstone entrance hall. Located at the other end of Messe Berlin, the Palais am Funkturm is only at a short distance from the CityCube.

18:45–19:15 Shuttle buses depart from the conference center to the evening event.

21:15–22:15 Shuttle buses depart from the evening event to all conference hotels.